Is AOD-9604 legal? FDA status, regulatory risks & 2026 update.

The current FDA status, in straightforward terms

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal 177-191 fragment of human growth hormone with an additional tyrosine residue at the N-terminus. It is not an FDA-approved drug for any indication. The Metabolic Pharmaceuticals development program of the late 1990s and 2000s did not result in a New Drug Application that the FDA approved, and the obesity development program was terminated in 2007 after the pivotal Phase 2b trial failed to show statistically significant weight loss versus placebo. No subsequent sponsor has produced a successful registrational program for the molecule. There is no FDA-approved AOD-9604 product on the US market.

AOD-9604 is also not a controlled substance. It does not appear on any schedule of the Controlled Substances Act. It is not in the same regulatory category as opioids, anabolic steroids, or similarly scheduled substances. That distinction matters, but it does not mean the peptide is freely available or legal to sell for human consumption. Those are different concepts.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), AOD-9604 does not meet the criteria for marketing as a dietary supplement under current FDA guidance. Any product marketed as a “peptide supplement” containing AOD-9604 is operating outside the dietary supplement framework regardless of how the label reads.

Where AOD-9604 sits, post April 15, 2026, is the FDA bulk drug substance Category 2 / transitional bucket. To understand what that means and why it is the load-bearing point on this page, the next section walks through the categorization framework.

The FDA category framework and the April 15, 2026 reshuffle

The FDA maintains category lists that determine which bulk drug substances a 503A compounding pharmacy may use. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions from licensed clinicians. The category framework is how the FDA tells those pharmacies which substances are permitted, which are prohibited, and which are still under review.

• Category 1 substances are those that 503A pharmacies may use under standard rules. These have a combination of safety, characterization, and history-of-use data the FDA considers adequate for compounding.
• Category 2 substances are those the FDA has determined raise sufficient safety, identity, or quality concerns that 503A pharmacies cannot compound them pending further review.
• Category 3 substances remain under active evaluation, with no final determination yet.

What changed on April 15, 2026

On April 15, 2026, the FDA reorganized its peptide categorization. The practical effect for AOD-9604 is that the peptide is treated as Category 2 / transitional for 503A compounding purposes. The reshuffle did not place AOD-9604 on the Category 1 permitted list, and it did not produce a clarifying determination that compounding could continue. Instead, the substance now sits in the bucket where 503A pharmacies cannot compound it pending Pharmacy Compounding Advisory Committee (PCAC) review.

Why this is the central fact

For a patient trying to figure out whether AOD-9604 is legally accessible through a legitimate medical pathway in the United States, this is the only fact that matters. A 503A pharmacy is the legitimate pathway. A 503A pharmacy cannot compound a Category 2 substance. AOD-9604 is treated as Category 2. Therefore there is no current legitimate compounding pathway for AOD-9604 through a 503A pharmacy in the United States.

We will say this directly, because it is necessary to be clear: 503A pharmacies cannot compound AOD-9604 today. PepScribe’s pharmacy standard is 503A-only by policy. PepScribe does not offer AOD-9604 as a peptide-direct compounded product. Clinics that source AOD-9604 outside the 503A standard are operating in a different framework. PepScribe operates inside the 503A framework only.

The compounding implication: why 503A matters

A reasonable question to ask is: if 503A pharmacies cannot compound AOD-9604, are there other compounding pathways? Two come up in conversation, and both warrant context.

503A versus other framings

Section 503A pharmacies prepare individualized compounded medications under a clinician’s prescription. They are the standard route through which Category 1 peptides reach patients via telehealth platforms. PepScribe works exclusively inside this framework, and we do not represent ourselves as anything else. When a peptide is Category 2, that route is closed.

Some clinics and supplement vendors source peptides through entirely different channels, including international suppliers, research-chemical vendors, and direct-from-manufacturer arrangements that fall outside the 503A pharmacy framework. Those channels do not provide the pharmaceutical-grade quality controls, identity verification, sterility testing, or chain-of-custody documentation that a US-licensed compounding pharmacy provides. A Category 2 designation does not grant any of those channels legitimacy.

What clinicians can and cannot prescribe

A licensed clinician in the United States can prescribe substances that are FDA-approved drugs, or that are eligible for compounding by a 503A pharmacy under FDA rules. AOD-9604 is neither. Even a clinician who personally believes the molecule has therapeutic potential cannot legitimately prescribe it through a 503A pathway in the current regulatory environment. There is no compounded product the prescription can attach to.

Some clinicians will, in practice, refer patients to non-503A sources or provide advisory guidance about gray-market products. PepScribe does not. Our clinicians work with the substances that are legitimately available under the 503A framework, and they have an honest conversation with the patient about the regulatory reality when a peptide is not.

Gray-market risks: what you are exposed to

Patients who hit the regulatory wall sometimes turn to unregulated sources, which include overseas peptide suppliers, research-chemical vendors selling under “not for human consumption” disclaimers, and underground channels of various kinds. We are not in the business of moralizing about personal choices. We are in the business of being honest about what those choices expose you to.

Purity and identity

Without a US-licensed compounding pharmacy in the chain, there is no pharmaceutical-grade quality assurance. Products sold as AOD-9604 from gray-market sources may contain:

• Incorrect peptide sequences, including truncated chains, partial synthesis products, or entirely different molecules altogether.
• Inaccurate concentrations, underdosed or overdosed relative to the label claim.
• Manufacturing residues, including solvent residues, heavy metals, and other contaminants from uncontrolled production processes.

Sterility, particularly for injectables

Injectable peptides require pharmaceutical-grade sterility. A 503A-compounded injectable is prepared under conditions designed to prevent bacterial endotoxin contamination, which is a serious risk for any product introduced parenterally. Gray-market injectable AOD-9604 is generally not produced under those conditions. Bacterial endotoxin contamination in injectable products can produce systemic reactions including fever, chills, and more severe outcomes.

Dosing and clinical oversight

Even if a gray-market product happened to contain accurate AOD-9604 at the stated concentration, self-administering an injectable peptide without clinician oversight removes the safeguards that catch interactions, contraindications, and adverse responses early. There is no prescriber reviewing your medical history, no follow-up bloodwork, and no documented pharmacovigilance pathway if something goes wrong.

Chain of custody and recourse

When a product comes through a US-licensed compounding pharmacy via a clinician’s prescription, there is documented chain of custody, an identified prescriber of record, and a regulatory framework for adverse event reporting. Gray-market products provide none of this. If something goes wrong, you have no meaningful recourse against an offshore research-chemical vendor.

The “research use only” disclaimer

Many gray-market AOD-9604 products are sold with “for research use only” or “not for human consumption” disclaimers. This language is a legal disclaimer used by suppliers to operate outside the pharmaceutical regulatory framework. It does not provide consumer protection. It does not establish quality or sterility. It does not create a legal pathway to self-administer the product. It is, in effect, a liability shield for the seller.

The Australian regulatory exception

A piece of context that comes up frequently in pro-AOD-9604 marketing is that the molecule received a self-affirmed Generally Recognized as Safe (GRAS) determination in the United States and that it has limited regulatory acceptance in some Australian health-food contexts. Here is what that means.

What GRAS is

Generally Recognized as Safe is a US food-ingredient safety pathway. A GRAS determination, whether self-affirmed by the sponsor or affirmed by the FDA, certifies that a substance is considered safe for use as a food ingredient under the conditions of its intended use. GRAS is not a drug approval. It does not authorize a substance for the treatment of any medical condition. It does not establish efficacy. And it does not extend to injectable or pharmaceutical use. AOD-9604’s GRAS designation is relevant for limited food-ingredient applications and is not relevant to the question of whether the peptide is approved as a therapeutic.

The Australian context

AOD-9604 was developed by an Australian company, Metabolic Pharmaceuticals, and it has had limited acceptance in some Australian health-food and supplement contexts. Australia’s Therapeutic Goods Administration (TGA), however, has not approved AOD-9604 as a registered therapeutic product. The TGA has historically taken a strict line on unapproved peptides, and Australian Border Force has seized peptide shipments at the border. The Australian regulatory environment for peptides is among the most restrictive globally, despite the molecule’s Australian origin.

Why this matters

The point is that “GRAS” and “Australian acceptance” are sometimes used in marketing copy as if they were equivalents to FDA drug approval. They are not. They are limited regulatory facts that do not authorize AOD-9604 as a therapeutic in any major jurisdiction.

International picture: UK, Canada, EU, Australia

If you are reading this from outside the United States, or if you are considering an international source, here is the broader picture.

United Kingdom

AOD-9604 is not licensed as a medicine by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. It cannot be legally sold or marketed as a medicine. The UK does not have a direct equivalent to the US 503A compounding framework that would create a legal pathway for the peptide as a therapeutic. Products available through research-chemical channels or supplement vendors operate outside the medicines regulatory framework.

Canada

Health Canada has not approved AOD-9604 as a drug or as a natural health product. It is not listed in the Drug Product Database or the Licensed Natural Health Products Database. Canadian compounding pharmacies operate under provincial regulation, and the legal pathway for compounding unapproved peptides is more restrictive than the US system. Importing AOD-9604 from international sources for personal use may run afoul of the Food and Drugs Act, particularly when the substance is represented for therapeutic use.

European Union

The European Medicines Agency (EMA) has not authorized AOD-9604 as a medicinal product, and there is no centrally authorized AOD-9604 product on the EU market. National regulators across member states broadly treat unauthorized peptides as outside the legitimate medicines framework. Specific national rules vary, and patients should consult local regulators rather than rely on summaries.

Australia

Despite the molecule’s Australian origin, the Therapeutic Goods Administration (TGA) has not approved AOD-9604 as a registered therapeutic good. As noted above, Australia’s peptide regulatory environment is among the most restrictive globally.

The international takeaway

No major regulatory jurisdiction has approved AOD-9604 for therapeutic use. The patchwork of food-ingredient and research-chemical channels that exists across countries does not provide the safety, quality, or legal protections of a regulated medical product anywhere.

WADA and athletic use

AOD-9604 falls within the World Anti-Doping Agency (WADA) prohibited list under the category of peptide hormones, growth factors, related substances, and mimetics. For competitive athletes subject to WADA jurisdiction, the peptide is prohibited.

• In and out of competition. The prohibition applies year-round, not only during competition periods.
• No realistic Therapeutic Use Exemption (TUE) pathway. Because AOD-9604 has no FDA-approved therapeutic indication, an athlete applying for a TUE has no basis to argue medical necessity.
• Detection methods are evolving. Anti-doping laboratories continue to develop and refine detection methods for synthetic peptides. The absence of a positive test today is not a guarantee of future undetectability.
• Consequences are severe. Multi-year competition bans, loss of titles and medals, financial penalties, and reputational damage are all possible outcomes of a positive test.
• The reach extends beyond elite athletes. Many collegiate, amateur, and professional sports organizations adopt WADA’s prohibited list or maintain their own.

If you are a competitive athlete at any level, consult the current WADA prohibited list directly (wada-ama.org/en/prohibited-list) and your sport’s anti-doping authority before considering any peptide.

Possession versus sale: the US distinction

A nuance that comes up in conversations about Category-unclassified peptides is the distinction between possessing a substance and selling it. They are governed by different legal concepts.

Possession of AOD-9604

Because AOD-9604 is not a controlled substance, simple possession of the peptide is not, on its own, a federal criminal offense in the way that possession of scheduled drugs is. State law varies, and state pharmacy boards have their own enforcement priorities, but federal possession charges in the controlled-substances sense are not the operative concern.

Selling AOD-9604 for human use

Selling a substance that has not been approved by the FDA as a drug, with marketing or representations suggesting human therapeutic use, raises a different set of issues. The FDA has historically taken enforcement action against companies marketing peptides with research-use disclaimers when the packaging, marketing context, or clinical pretense suggests the products are intended for human consumption. State consumer-protection laws may impose additional penalties on misrepresentation.

Importation

Importing peptides for personal use carries its own regulatory exposure. US Customs and Border Protection may seize shipments of unapproved peptides, particularly when products are clearly marketed for human consumption. The legal exposure here is generally regulatory rather than criminal in the controlled-substances sense, but it is real.

Why this matters less than vendors imply

The argument vendors sometimes make, that “possession is not illegal,” is technically true and substantively beside the point. Possession not being criminal does not mean the regulatory pathway is open. It does not mean the product is safe. It does not mean a legitimate pharmacy can compound it. And it does not turn a research-chemical purchase into a legitimate medical pathway.

What reclassification would require

A common question is whether AOD-9604 might move from transitional Category 2 status to a permitted Category 1 status, opening up a 503A compounding pathway. The honest answer is that it could happen, but the bar is real, and there is no near-term timeline.

The PCAC review process

The Pharmacy Compounding Advisory Committee (PCAC) is the FDA advisory panel that reviews bulk drug substances for inclusion on the Category 1 list. PCAC review involves evaluation of the available human safety and efficacy data, identity and characterization standards, history of use, and clinical rationale. The committee makes recommendations, and the FDA acts on them. The peptide review work that was triggered by the broader category reshuffle is ongoing through 2026 and 2027.

The substantive bar

For PCAC to recommend Category 1 status for a peptide, the substance generally needs an adequate human safety record, a defensible clinical use case, and identity standards that allow for reproducible compounding. AOD-9604 has acceptable short-term tolerability data from the Phase 1 and Phase 2 trials, which is in its favor. It also has the null Phase 2b weight-loss result, which is not in its favor. The exact path to Category 1 status, if any, is unclear.

What it would not require

Reclassification would not require new FDA drug approval, new clinical trials of registrational scope, or a New Drug Application from a sponsor. It is a more limited regulatory question about whether 503A pharmacies may compound the substance, not whether the peptide is approved as a drug. So the bar is not impossibly high. It is also not low.

Currently available alternatives for weight management

Most patients who arrive at the AOD-9604 conversation are pursuing weight management. The pragmatic answer for that goal is that the available evidence base for GLP-1 receptor agonists is in a different league.

• Semaglutide is a GLP-1 receptor agonist with an FDA-approved branded product line for weight management and a clinician-prescribed compounded equivalent available through 503A pharmacies. The registrational evidence base includes large Phase 3 trials with weight-loss outcomes that AOD-9604 did not reproduce.
• Tirzepatide is a dual GIP/GLP-1 receptor agonist with an FDA-approved branded product line for weight management and a clinician-prescribed compounded equivalent available through 503A pharmacies. The Phase 3 weight-loss outcomes are larger than those for semaglutide alone.

Both work through entirely different mechanisms than AOD-9604, both have regulatory pathways open today, and both can be evaluated and prescribed through a clinician-supervised consultation.

Frequently asked questions about AOD-9604 legality

Is AOD-9604 a controlled substance?

No. AOD-9604 is not listed on any schedule of the US Controlled Substances Act. Simple possession does not carry the criminal penalties associated with scheduled drugs.

Can I get AOD-9604 from a compounding pharmacy right now?

Not from a 503A pharmacy. Following the April 15, 2026 reshuffle, AOD-9604 sits in the transitional Category 2 bucket, and 503A pharmacies cannot compound it. PepScribe operates inside the 503A standard exclusively, so we do not offer the peptide as a compounded product.

What about clinics that say they can prescribe AOD-9604?

Some clinics source peptides outside the 503A framework, including through international suppliers, research-chemical vendors, or direct-from-manufacturer arrangements. Those routes do not provide the pharmaceutical-grade quality controls of a US-licensed compounding pharmacy. PepScribe does not operate through those routes.

Is buying AOD-9604 online illegal?

Legality depends on jurisdiction, the seller’s representations, and intended use. Products labeled “for research use only” occupy a regulatory uncertainty. They are not manufactured to pharmaceutical standards, are not intended or approved for human use, and do not provide the protections of a regulated medical pathway.

Is AOD-9604 legal in Canada, the UK, or Australia?

AOD-9604 is not approved as a therapeutic product in any of these jurisdictions. National regulatory frameworks vary, but none provide a clear legitimate pathway for therapeutic use. Australia’s framework is among the most restrictive globally despite the molecule’s Australian origin.

Will AOD-9604 ever become legal again for compounding?

Possibly. The PCAC continues to review peptides through 2026 and 2027. Reclassification to Category 1 would require an evaluation of safety, identity, and clinical-use data that AOD-9604 may or may not clear given the null Phase 2b weight-loss outcome. There is no guaranteed timeline.

Is AOD-9604 a dietary supplement?

No. AOD-9604 is not authorized as a dietary supplement ingredient under current FDA guidance. The self-affirmed GRAS food-ingredient status that exists for limited contexts is not a substitute for dietary supplement or drug authorization.

What can I do for weight management today?

Talk to a clinician about GLP-1 receptor agonist therapy. Both Semaglutide and Tirzepatide are available through clinician-supervised programs with substantial registrational evidence bases for weight management.

Summary table: AOD-9604 status by jurisdiction

AOD-9604 sits in a regulatory ambiguity in every major jurisdiction we surveyed. It is not criminalized for simple possession in most places, but it is also not legally available through any regulated medical pathway. In the United States, the April 15, 2026 reshuffle leaves it in Category 2, which closes the 503A compounding route that would otherwise be the legitimate path.

The most responsible course of action is to stay informed, consult a licensed clinician, and explore the peptide therapies that are legally available today, particularly the GLP-1 receptor agonist family for weight-management goals.